The Status of MUSIC: The Multiwavelength Sub/millimeter Inductance Camera

The Multiwavelength Sub/millimeter Inductance Camera (MUSIC) is a four-band photometric imaging camera operating from the Caltech Submillimeter Observatory (CSO). MUSIC is designed to utilize 2304 microwave kinetic inductance detectors (MKIDs), with 576 MKIDs for each observing band centered on 150, 230, 290, and 350 GHz. MUSIC’s field of view (FOV) is 14′ square, and the point-spread functions (PSFs) in the four observing bands have 45′′, 31′′, 25′′, and 22′′ full-widths at half maximum (FWHM). The camera was installed in April 2012 with 25% of its nominal detector count in each band, and has subsequently completed three short sets of engineering observations and one longer duration set of early science observations. Recent results from on-sky characterization of the instrument during these observing runs are presented, including achieved map- based sensitivities from deep integrations, along with results from lab-based measurements made during the same period. In addition, recent upgrades to MUSIC, which are expected to significantly improve the sensitivity of the camera, are described

Optics for MUSIC: a new (sub)millimeter camera for the Caltech Submillimeter Observatory

We will present the design and implementation, along with calculations and some measurements of the performance, of the room-temperature and cryogenic optics for MUSIC, a new (sub)millimeter camera we are developing for the Caltech Submm Observatory (CSO). The design consists of two focusing elements in addition to the CSO primary and secondary mirrors: a warm off-axis elliptical mirror and a cryogenic (4K) lens. These optics will provide a 14 arcmin field of view that is diffraction limited in all four of the MUSIC observing bands (2.00, 1.33, 1.02, and 0.86 mm). A cold (4K) Lyot stop will be used to define the primary mirror illumination, which will be maximized while keeping spillover at the sub 1% level. The MUSIC focal plane will be populated with broadband phased antenna arrays that efficiently couple to factor of (see manuscript) 3 in bandwidth, and each pixel on the focal plane will be read out via a set of four lumped element filters that define the MUSIC observing bands (i.e., each pixel on the focal plane simultaneously observes in all four bands). Finally, a series of dielectric and metal-mesh low pass filters have been implemented to reduce the optical power load on the MUSIC cryogenic stages to a quasi-negligible level while maintaining good transmission in-band

MUSIC for sub/millimeter astrophysics

MUSIC (the Multiwavelength Submillimeter kinetic Inductance Camera) is an instrument being developed for the Caltech Submillimeter Observatory by Caltech, JPL, the University of Colorado, and UCSB. MUSIC uses microwave kinetic inductance detectors (MKIDs) - superconducting micro-resonators - as photon detectors. The readout is almost entirely at room temperature and is highly multiplexed. MUSIC will have 576 spatial pixels in four bands at 850, 1100, 1300 and 2000 microns. MUSIC is scheduled for deployment at the CSO in the winter of 2010/2011. We present an overview of the camera design and readout and describe the current status of the instrument and some results from the highly successful May/June 2010 observing run at the CSO with the prototype camera, which verified the performance of the complete system (optics, antennas/filters, resonators, and readout) and produced the first simultaneous 3-color observations with any MKID camera

MUSIC for sub/millimeter astrophysics

MUSIC (the Multiwavelength Submillimeter kinetic Inductance Camera) is an instrument being developed for the Caltech Submillimeter Observatory by Caltech, JPL, the University of Colorado, and UCSB. MUSIC uses microwave kinetic inductance detectors (MKIDs) - superconducting micro-resonators - as photon detectors. The readout is almost entirely at room temperature and is highly multiplexed. MUSIC will have 576 spatial pixels in four bands at 850, 1100, 1300 and 2000 microns. MUSIC is scheduled for deployment at the CSO in the winter of 2010/2011. We present an overview of the camera design and readout and describe the current status of the instrument and some results from the highly successful May/June 2010 observing run at the CSO with the prototype camera, which verified the performance of the complete system (optics, antennas/filters, resonators, and readout) and produced the first simultaneous 3-color observations with any MKID camera

Optics for MUSIC: a new (sub)millimeter camera for the Caltech Submillimeter Observatory

We will present the design and implementation, along with calculations and some measurements of the performance, of the room-temperature and cryogenic optics for MUSIC, a new (sub)millimeter camera we are developing for the Caltech Submm Observatory (CSO). The design consists of two focusing elements in addition to the CSO primary and secondary mirrors: a warm off-axis elliptical mirror and a cryogenic (4K) lens. These optics will provide a 14 arcmin field of view that is diffraction limited in all four of the MUSIC observing bands (2.00, 1.33, 1.02, and 0.86 mm). A cold (4K) Lyot stop will be used to define the primary mirror illumination, which will be maximized while keeping spillover at the sub 1% level. The MUSIC focal plane will be populated with broadband phased antenna arrays that efficiently couple to factor of (see manuscript) 3 in bandwidth, and each pixel on the focal plane will be read out via a set of four lumped element filters that define the MUSIC observing bands (i.e., each pixel on the focal plane simultaneously observes in all four bands). Finally, a series of dielectric and metal-mesh low pass filters have been implemented to reduce the optical power load on the MUSIC cryogenic stages to a quasi-negligible level while maintaining good transmission in-band

BioTIME:a database of biodiversity time series for the Anthropocene

Abstract Motivation: The BioTIME database contains raw data on species identities and abundances in ecological assemblages through time. These data enable users to calculate temporal trends in biodiversity within and amongst assemblages using a broad range of metrics. BioTIME is being developed as a community‐led open‐source database of biodiversity time series. Our goal is to accelerate and facilitate quantitative analysis of temporal patterns of biodiversity in the Anthropocene. Main types of variables included: The database contains 8,777,413 species abundance records, from assemblages consistently sampled for a minimum of 2 years, which need not necessarily be consecutive. In addition, the database contains metadata relating to sampling methodology and contextual information about each record. Spatial location and grain: BioTIME is a global database of 547,161 unique sampling locations spanning the marine, freshwater and terrestrial realms. Grain size varies across datasets from 0.0000000158 km² (158 cm²) to 100 km² (1,000,000,000,000 cm²). Time period and grain: BioTIME records span from 1874 to 2016. The minimal temporal grain across all datasets in BioTIME is a year. Major taxa and level of measurement: BioTIME includes data from 44,440 species across the plant and animal kingdoms, ranging from plants, plankton and terrestrial invertebrates to small and large vertebrates. Software format: .csv and .SQL

Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial

We aimed to assess the efficacy and safety of two neutralising monoclonal antibody therapies (sotrovimab [Vir Biotechnology and GlaxoSmithKline] and BRII-196 plus BRII-198 [Brii Biosciences]) for adults admitted to hospital for COVID-19 (hereafter referred to as hospitalised) with COVID-19. In this multinational, double-blind, randomised, placebo-controlled, clinical trial (Therapeutics for Inpatients with COVID-19 [TICO]), adults (aged ≥18 years) hospitalised with COVID-19 at 43 hospitals in the USA, Denmark, Switzerland, and Poland were recruited. Patients were eligible if they had laboratory-confirmed SARS-CoV-2 infection and COVID-19 symptoms for up to 12 days. Using a web-based application, participants were randomly assigned (2:1:2:1), stratified by trial site pharmacy, to sotrovimab 500 mg, matching placebo for sotrovimab, BRII-196 1000 mg plus BRII-198 1000 mg, or matching placebo for BRII-196 plus BRII-198, in addition to standard of care. Each study product was administered as a single dose given intravenously over 60 min. The concurrent placebo groups were pooled for analyses. The primary outcome was time to sustained clinical recovery, defined as discharge from the hospital to home and remaining at home for 14 consecutive days, up to day 90 after randomisation. Interim futility analyses were based on two seven-category ordinal outcome scales on day 5 that measured pulmonary status and extrapulmonary complications of COVID-19. The safety outcome was a composite of death, serious adverse events, incident organ failure, and serious coinfection up to day 90 after randomisation. Efficacy and safety outcomes were assessed in the modified intention-to-treat population, defined as all patients randomly assigned to treatment who started the study infusion. This study is registered with ClinicalTrials.gov, NCT04501978. Between Dec 16, 2020, and March 1, 2021, 546 patients were enrolled and randomly assigned to sotrovimab (n=184), BRII-196 plus BRII-198 (n=183), or placebo (n=179), of whom 536 received part or all of their assigned study drug (sotrovimab n=182, BRII-196 plus BRII-198 n=176, or placebo n=178; median age of 60 years [IQR 50–72], 228 [43%] patients were female and 308 [57%] were male). At this point, enrolment was halted on the basis of the interim futility analysis. At day 5, neither the sotrovimab group nor the BRII-196 plus BRII-198 group had significantly higher odds of more favourable outcomes than the placebo group on either the pulmonary scale (adjusted odds ratio sotrovimab 1·07 [95% CI 0·74–1·56]; BRII-196 plus BRII-198 0·98 [95% CI 0·67–1·43]) or the pulmonary-plus complications scale (sotrovimab 1·08 [0·74–1·58]; BRII-196 plus BRII-198 1·00 [0·68–1·46]). By day 90, sustained clinical recovery was seen in 151 (85%) patients in the placebo group compared with 160 (88%) in the sotrovimab group (adjusted rate ratio 1·12 [95% CI 0·91–1·37]) and 155 (88%) in the BRII-196 plus BRII-198 group (1·08 [0·88–1·32]). The composite safety outcome up to day 90 was met by 48 (27%) patients in the placebo group, 42 (23%) in the sotrovimab group, and 45 (26%) in the BRII-196 plus BRII-198 group. 13 (7%) patients in the placebo group, 14 (8%) in the sotrovimab group, and 15 (9%) in the BRII-196 plus BRII-198 group died up to day 90. Neither sotrovimab nor BRII-196 plus BRII-198 showed efficacy for improving clinical outcomes among adults hospitalised with COVID-19. US National Institutes of Health and Operation Warp Spee

Geoeconomic variations in epidemiology, ventilation management, and outcomes in invasively ventilated intensive care unit patients without acute respiratory distress syndrome: a pooled analysis of four observational studies

Background: Geoeconomic variations in epidemiology, the practice of ventilation, and outcome in invasively ventilated intensive care unit (ICU) patients without acute respiratory distress syndrome (ARDS) remain unexplored. In this analysis we aim to address these gaps using individual patient data of four large observational studies. Methods: In this pooled analysis we harmonised individual patient data from the ERICC, LUNG SAFE, PRoVENT, and PRoVENT-iMiC prospective observational studies, which were conducted from June, 2011, to December, 2018, in 534 ICUs in 54 countries. We used the 2016 World Bank classification to define two geoeconomic regions: middle-income countries (MICs) and high-income countries (HICs). ARDS was defined according to the Berlin criteria. Descriptive statistics were used to compare patients in MICs versus HICs. The primary outcome was the use of low tidal volume ventilation (LTVV) for the first 3 days of mechanical ventilation. Secondary outcomes were key ventilation parameters (tidal volume size, positive end-expiratory pressure, fraction of inspired oxygen, peak pressure, plateau pressure, driving pressure, and respiratory rate), patient characteristics, the risk for and actual development of acute respiratory distress syndrome after the first day of ventilation, duration of ventilation, ICU length of stay, and ICU mortality. Findings: Of the 7608 patients included in the original studies, this analysis included 3852 patients without ARDS, of whom 2345 were from MICs and 1507 were from HICs. Patients in MICs were younger, shorter and with a slightly lower body-mass index, more often had diabetes and active cancer, but less often chronic obstructive pulmonary disease and heart failure than patients from HICs. Sequential organ failure assessment scores were similar in MICs and HICs. Use of LTVV in MICs and HICs was comparable (42·4% vs 44·2%; absolute difference -1·69 [-9·58 to 6·11] p=0·67; data available in 3174 [82%] of 3852 patients). The median applied positive end expiratory pressure was lower in MICs than in HICs (5 [IQR 5-8] vs 6 [5-8] cm H2O; p=0·0011). ICU mortality was higher in MICs than in HICs (30·5% vs 19·9%; p=0·0004; adjusted effect 16·41% [95% CI 9·52-23·52]; p<0·0001) and was inversely associated with gross domestic product (adjusted odds ratio for a US$10 000 increase per capita 0·80 [95% CI 0·75-0·86]; p<0·0001). Interpretation: Despite similar disease severity and ventilation management, ICU mortality in patients without ARDS is higher in MICs than in HICs, with a strong association with country-level economic status